HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yongli Yu Selected Research

CPG-oligonucleotide

10/2017Protective role of surface Toll-like receptor 9 expressing neutrophils in local inflammation during systemic inflammatory response syndrome in mice.
12/2016Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice.
1/2016Delivery System of CpG Oligodeoxynucleotides through Eliciting an Effective T cell Immune Response against Melanoma in Mice.
8/2013Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo.
12/2012Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3.
8/2012MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
2/2012A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice.
3/2010A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways.
6/2009Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice.
2/2006Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yongli Yu Research Topics

Disease

20Neoplasms (Cancer)
11/2020 - 05/2006
7Infections
07/2020 - 04/2010
6Experimental Melanoma
01/2016 - 04/2010
4Melanoma (Melanoma, Malignant)
10/2017 - 04/2010
3Acute Lung Injury
01/2020 - 01/2017
3Myocarditis (Carditis)
10/2019 - 10/2007
3Breast Neoplasms (Breast Cancer)
05/2017 - 06/2009
3Thyroid Neoplasms (Thyroid Cancer)
08/2012 - 03/2010
3Neoplasm Metastasis (Metastasis)
08/2012 - 03/2010
2Glioma (Gliomas)
12/2018 - 11/2015
2Inflammation (Inflammations)
10/2017 - 01/2017
2Shock
10/2017 - 03/2010
2Systemic Inflammatory Response Syndrome (Sepsis Syndrome)
10/2017 - 01/2014
2Peritonitis
05/2017 - 01/2016
2Bronchiolitis Obliterans Syndrome
03/2012 - 09/2011
2Lupus Nephritis
03/2012 - 09/2011
1Bites and Stings (Sting)
10/2021
1Heart Injuries
10/2019
1Mycoses (Diseases, Fungus)
01/2019
1Sepsis (Septicemia)
01/2019
1Splenomegaly
12/2018
1Burns
01/2017
1Bacterial Infections (Bacterial Infection)
01/2016
1Pancreatic Neoplasms (Pancreatic Cancer)
07/2015
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
06/2015
1Wounds and Injuries (Trauma)
01/2014
1Carcinogenesis
08/2013
1Arthritis (Polyarthritis)
12/2012
1Synovitis
12/2012
1Body Weight (Weight, Body)
12/2012
1Brain Neoplasms (Brain Tumor)
08/2012
1Follicular Adenocarcinoma
08/2012
1Colorectal Neoplasms (Colorectal Cancer)
06/2012
1Liver Neoplasms (Liver Cancer)
05/2012

Drug/Important Bio-Agent (IBA)

14OligodeoxyribonucleotidesIBA
10/2017 - 02/2006
10CPG-oligonucleotideIBA
10/2017 - 02/2006
8VaccinesIBA
11/2020 - 06/2010
8Proteins (Proteins, Gene)FDA Link
12/2018 - 05/2006
6Heat-Shock Proteins (Heat-Shock Protein)IBA
11/2015 - 05/2006
5Cancer VaccinesIBA
01/2016 - 04/2010
4CytokinesIBA
11/2020 - 01/2017
4Toll-Like Receptor 9IBA
10/2019 - 12/2012
4Immunoglobulin G (IgG)IBA
05/2017 - 12/2010
4AntibodiesIBA
12/2016 - 04/2010
4Peptides (Polypeptides)IBA
02/2013 - 05/2006
4Therapeutic UsesIBA
08/2012 - 02/2011
3Interferon Type IIBA
10/2021 - 12/2010
3Interferon Regulatory FactorsIBA
10/2019 - 01/2017
3Recombinant ProteinsIBA
12/2018 - 05/2006
3AntigensIBA
05/2017 - 04/2010
3SAT05fIBA
11/2011 - 03/2010
2Immune Checkpoint InhibitorsIBA
11/2020 - 10/2017
2InterferonsIBA
07/2020 - 05/2012
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2019 - 01/2017
2Interleukin-6 (Interleukin 6)IBA
10/2019 - 01/2017
2ImmunosorbentsIBA
05/2017 - 12/2010
2EnzymesIBA
05/2017 - 12/2010
2Mucin-1 (CA 15-3 Antigen)IBA
05/2017 - 12/2010
2EpitopesIBA
12/2016 - 05/2006
2Neoplasm Antigens (Tumor Antigens)IBA
01/2014 - 04/2010
2GuanosineIBA
08/2013 - 12/2010
2Sorafenib (BAY 43-9006)FDA Link
08/2012 - 02/2011
2AutoantibodiesIBA
03/2012 - 12/2010
2Antigen-Antibody Complex (Immune Complex)IBA
03/2012 - 12/2010
2DNA (Deoxyribonucleic Acid)IBA
09/2011 - 06/2008
2Imiquimod (Aldara)FDA LinkGeneric
12/2010 - 03/2010
1ManganeseIBA
10/2021
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
07/2020
1LigandsIBA
07/2020
1Indicators and Reagents (Reagents)IBA
01/2019
1PesticidesIBA
01/2019
1Interferon Regulatory Factor-7 (Interferon Regulatory Factor 7)IBA
01/2019
1ThiramFDA Link
01/2019
1FlagellinIBA
12/2018
1B-Lymphocyte Epitopes (B-Cell Epitope)IBA
12/2018
1NivolumabIBA
10/2017
1sargramostim (Leukine)FDA Link
10/2017
1pembrolizumabIBA
10/2017
1IpilimumabIBA
10/2017
1GalactosamineIBA
10/2017
1Synthetic Vaccines (Recombinant Vaccines)IBA
12/2016
1Interleukin-17 (Interleukin 17)IBA
01/2016
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2015
1Prednisone (Sone)FDA LinkGeneric
06/2015
1Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
06/2015
1Recombinant Fusion ProteinsIBA
01/2014
1Mitochondrial DNA (mtDNA)IBA
01/2014
1human ERBB2 proteinIBA
02/2013
1incomplete Freund's adjuvantIBA
12/2012
1Freund's AdjuvantIBA
12/2012
1EmulsionsIBA
12/2012
1Neutralizing AntibodiesIBA
12/2012
1Dihydrotachysterol (AT 10)IBA
12/2012
1RacivirIBA
08/2012
1MF59 oil emulsionIBA
08/2012

Therapy/Procedure

9Therapeutics
10/2017 - 02/2006
2Immunotherapy
12/2018 - 07/2015
1Intraperitoneal Injections
10/2017
1Intradermal Injections
12/2012
1Quantum Dots (Quantum Dot)
06/2012